Roy Lee Silverstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Roy Lee Silverstein has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Yiliang Chen
Versiti Blood Research Institute, Milwaukee, WI (Y.W., Q.Q.L., H.T., Z.Z., R.L.S., Y.C.).
13 shared publications - Moua Yang
University of Washington School of Medicine, Seattle, Washington, United States
9 shared publications Wenxin Huang
From the Blood Research Institute, Versiti, Blood Center of Wisconsin, Milwaukee (Y.C., W.H., Y.Z., M.L.S., Z.G., W. Cui, S.M., R.L.S.).
5 shared publicationsGang Xin
4 shared publicationsJoseph I. Shapiro
Department of Medicine, University of Toledo, OH (J.I.S.).
4 shared publications- Wei Li
Department of Biomedical Sciences, Joan C. Edwards School of Medicine at Marshall University
4 shared publications
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (10)
Na/K-ATPase Signaling in Adipocytes Promotes Atherosclerosis
BACKGROUND: Adipocyte dysfunction is closely associated with oxidative stress and chronic inflammation, which contribute to systemic metabolic disturbances and atherosclerosis. We previously identified the NKA (Na/K-ATPase) α1 subunit as a signal transducer that activates Src-family kinases and promotes oxidative stress and inflammation in various cell types, including adipocytes and macrophages. NaKtide, a peptide inhibitor of NKA signaling, has been shown to reduce systemic oxidative stress and inflammation in vivo. In this study, we investigated the role of adipocyte-specific NKA signaling in atherosclerosis. METHODS: Adipocyte-specific NaKtide was delivered to Apoe −/− mice using a lentiviral vector under the adiponectin promoter. The mice were then fed a Western diet for 12 weeks to induce atherosclerosis and then assessed for atherosclerotic plaque burden in the aortic arch and at the level of the aortic sinus. Inflammatory and oxidative stress markers were analyzed in adipose tissue and plasma. RESULTS: Adipocyte-specific NaKtide reduced atherosclerotic plaque area by 67% in the aortic arch and by 48% in the aortic sinus. CD68+ (cluster of differentiation 68) macrophage content and α-SMA+ (α-smooth muscle actin) smooth muscle cell content in the aortic sinus were decreased by 45% and 53%, respectively. These vascular improvements were accompanied by dampened adipose tissue inflammation and oxidative stress, improved glucose tolerance, and reduced systemic inflammation. CONCLUSIONS: These findings highlight a critical contributing role for adipocyte NKA signaling in atherosclerosis, suggesting an important endocrine and paracrine influence of adipose tissue on large artery atherogenesis and supporting the therapeutic potential of targeting NKA in cardiometabolic disease.
- 1 October 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (10)
Na/K-ATPase Signaling in Adipocytes Promotes Atherosclerosis
BACKGROUND: Adipocyte dysfunction is closely associated with oxidative stress and chronic inflammation, which contribute to systemic metabolic disturbances and atherosclerosis. We previously identified the NKA (Na/K-ATPase) α1 subunit as a signal transducer that activates Src-family kinases and promotes oxidative stress and inflammation in various cell types, including adipocytes and macrophages. NaKtide, a peptide inhibitor of NKA signaling, has been shown to reduce systemic oxidative stress and inflammation in vivo. In this study, we investigated the role of adipocyte-specific NKA signaling in atherosclerosis. METHODS: Adipocyte-specific NaKtide was delivered to Apoe −/− mice using a lentiviral vector under the adiponectin promoter. The mice were then fed a Western diet for 12 weeks to induce atherosclerosis and then assessed for atherosclerotic plaque burden in the aortic arch and at the level of the aortic sinus. Inflammatory and oxidative stress markers were analyzed in adipose tissue and plasma. RESULTS: Adipocyte-specific NaKtide reduced atherosclerotic plaque area by 67% in the aortic arch and by 48% in the aortic sinus. CD68+ (cluster of differentiation 68) macrophage content and α-SMA+ (α-smooth muscle actin) smooth muscle cell content in the aortic sinus were decreased by 45% and 53%, respectively. These vascular improvements were accompanied by dampened adipose tissue inflammation and oxidative stress, improved glucose tolerance, and reduced systemic inflammation. CONCLUSIONS: These findings highlight a critical contributing role for adipocyte NKA signaling in atherosclerosis, suggesting an important endocrine and paracrine influence of adipose tissue on large artery atherogenesis and supporting the therapeutic potential of targeting NKA in cardiometabolic disease.
- 1 September 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (9)
Macrophage PIM1 Drives Atherosclerosis by Enhancing Foam Cell Formation Via CD36
BACKGROUND: Atherosclerosis is characterized by the buildup of fatty plaques that thicken and stiffen arterial walls. Mφs (macrophages) significantly contribute to this process through their scavenger receptor CD36 (cluster of differentiation 36). PIM1 (proviral integration site for Moloney murine leukemia virus 1) is a serine/threonine kinase known to modulate immune responses and cell metabolism. However, its role in Mφ lipid handling and atherogenesis is not well defined. This study examines the role of PIM1 in regulating CD36 expression and function in Mφs during foam cell formation and atherosclerosis progression. METHODS: We performed in vitro studies by treating murine peritoneal Mφs from Pim1 −/− and wild-type mice with oxLDL (oxidized low-density lipoprotein). We measured CD36, PIM1, and plaque-associated proteins and mRNA levels, oxLDL binding and uptake rates, and foam cell formation. For in vivo studies, we fed myeloid-specific Pim1 -deficient ( Apoe −/− Lyz2 Cre/+ Pim1 fl/fl ) and their littermate control ( Apoe −/− Pim1 fl/fl ) mice a high-fat diet for 12 weeks. We then evaluated plaque formation in their aortic sinuses and arches. RESULTS: Deletion of Pim1 in Mφs reduced CD36 protein expression by up to 96.7% compared with wild-type controls. This led to a 49.6% decrease in foam cell formation and a 25.5% reduction in cellular cholesterol after oxLDL treatment. Pharmacological inhibition of PIM kinase activity in wild-type Mφs also impaired oxLDL handling, with a 64.5% reduction in binding and a 57.9% reduction in uptake. Bulk RNA-sequencing revealed that Pim1 deficiency downregulated PPARγ (peroxisome proliferator-activated receptor gamma) signaling. Treatment with a PPARγ agonist restored CD36 levels in the Pim1 knockdown Mφs, suggesting that PIM1 regulates CD36 through PPARγ. Moreover, Pim1 myeloid–specific deficiency caused a 69.4% reduction in atherosclerotic plaque formation. CONCLUSIONS: PIM1 acts as a key upstream regulator of CD36 by enhancing PPARγ activity in Mφs. The PIM1-CD36 axis promotes oxLDL binding, uptake, and foam cell formation. Targeting the PIM1/PPARγ/CD36 pathway could offer new ways to modulate Mφ lipid metabolism and reduce atherosclerotic plaque progression.
- 1 September 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (9)
Macrophage PIM1 Drives Atherosclerosis by Enhancing Foam Cell Formation Via CD36
BACKGROUND: Atherosclerosis is characterized by the buildup of fatty plaques that thicken and stiffen arterial walls. Mφs (macrophages) significantly contribute to this process through their scavenger receptor CD36 (cluster of differentiation 36). PIM1 (proviral integration site for Moloney murine leukemia virus 1) is a serine/threonine kinase known to modulate immune responses and cell metabolism. However, its role in Mφ lipid handling and atherogenesis is not well defined. This study examines the role of PIM1 in regulating CD36 expression and function in Mφs during foam cell formation and atherosclerosis progression. METHODS: We performed in vitro studies by treating murine peritoneal Mφs from Pim1 −/− and wild-type mice with oxLDL (oxidized low-density lipoprotein). We measured CD36, PIM1, and plaque-associated proteins and mRNA levels, oxLDL binding and uptake rates, and foam cell formation. For in vivo studies, we fed myeloid-specific Pim1 -deficient ( Apoe −/− Lyz2 Cre/+ Pim1 fl/fl ) and their littermate control ( Apoe −/− Pim1 fl/fl ) mice a high-fat diet for 12 weeks. We then evaluated plaque formation in their aortic sinuses and arches. RESULTS: Deletion of Pim1 in Mφs reduced CD36 protein expression by up to 96.7% compared with wild-type controls. This led to a 49.6% decrease in foam cell formation and a 25.5% reduction in cellular cholesterol after oxLDL treatment. Pharmacological inhibition of PIM kinase activity in wild-type Mφs also impaired oxLDL handling, with a 64.5% reduction in binding and a 57.9% reduction in uptake. Bulk RNA-sequencing revealed that Pim1 deficiency downregulated PPARγ (peroxisome proliferator-activated receptor gamma) signaling. Treatment with a PPARγ agonist restored CD36 levels in the Pim1 knockdown Mφs, suggesting that PIM1 regulates CD36 through PPARγ. Moreover, Pim1 myeloid–specific deficiency caused a 69.4% reduction in atherosclerotic plaque formation. CONCLUSIONS: PIM1 acts as a key upstream regulator of CD36 by enhancing PPARγ activity in Mφs. The PIM1-CD36 axis promotes oxLDL binding, uptake, and foam cell formation. Targeting the PIM1/PPARγ/CD36 pathway could offer new ways to modulate Mφ lipid metabolism and reduce atherosclerotic plaque progression.
- Open Access
Macrophage PIM1 Drives Atherosclerosis by Enhancing Foam Cell Formation Via CD36
Background: Atherosclerosis is characterized by the buildup of fatty plaques that thicken and stiffen arterial walls. Macrophages (Mφs) significantly contribute to this process through their scavenger receptor CD36. PIM1 is a serine/threonine kinase known to modulate immune responses and cell metabolism. However, its role in Mφ lipid handling and atherogenesis is not well defined. This study examines the role of PIM1 in regulating CD36 expression and function in Mφs during foam cell formation and atherosclerosis progression. Methods: We performed in vitro studies by treating murine peritoneal Mφs from Pim1 -/- and wild-type (WT) mice with oxidized low-density lipoprotein (oxLDL). We measured CD36, PIM1, and plaque-associated proteins and mRNA levels, oxLDL binding and uptake rates, as well as foam cell formation. For in vivo studies, we fed Mφ-specific PIM1-deficient ( Apoe -/- Lyz2 Cre/+ Pim1 fl/fl ) and their littermate control ( Apoe ⁻/⁻ Pim1 fl/fl ) mice a high-fat diet for 12 weeks. We then evaluated the plaque formation in their aortic sinuses and arches. Results: Deletion of Pim1 in Mφs reduced CD36 protein expression by up to 96.7% compared to WT controls. This led to a 49.6% decrease in foam cell formation and a 25.5% reduction in cellular cholesterol after oxLDL treatment. Pharmacological inhibition of PIM kinase activity in WT Mφs also impaired oxLDL handling, with a 64.5% reduction in binding and a 57.9% in uptake. Bulk RNA-seq revealed that Pim1 deficiency downregulated PPARγ signaling. Treatment with a PPARγ agonist restored CD36 levels in the PIM1 knockdown Mφs, suggesting that PIM1 regulates CD36 through PPARγ. Moreover, PIM1 Mφ-specific deficiency caused a 69.4% reduction in atherosclerotic plaque formation. Conclusion: PIM1 acts as a key upstream regulator of CD36 by enhancing PPARγ activity in Mφs. The PIM1-CD36 axis promotes oxLDL binding, uptake, and foam cell formation. Targeting the PIM1/PPARγ/CD36 pathway could offer new ways to modulate Mφ lipid metabolism and reduce atherosclerotic plaque progression. Non-standard Abbreviations and Acronyms: ELISA: enzyme-linked immunosorbent assay; HFD: high-fat diet; Mφs: macrophages; MCP-1: monocyte chemoattractant protein-1; ORO: oil red O; oxLDL: oxidized low-density lipoprotein; PBS: phosphate-buffered saline; PPARγ: peroxisome proliferator-activated receptor gamma; WT: wild type.
Open AccessMacrophage PIM1 Drives Atherosclerosis by Enhancing Foam Cell Formation Via CD36
Background: Atherosclerosis is characterized by the buildup of fatty plaques that thicken and stiffen arterial walls. Macrophages (Mφs) significantly contribute to this process through their scavenger receptor CD36. PIM1 is a serine/threonine kinase known to modulate immune responses and cell metabolism. However, its role in Mφ lipid handling and atherogenesis is not well defined. This study examines the role of PIM1 in regulating CD36 expression and function in Mφs during foam cell formation and atherosclerosis progression. Methods: We performed in vitro studies by treating murine peritoneal Mφs from Pim1 -/- and wild-type (WT) mice with oxidized low-density lipoprotein (oxLDL). We measured CD36, PIM1, and plaque-associated proteins and mRNA levels, oxLDL binding and uptake rates, as well as foam cell formation. For in vivo studies, we fed Mφ-specific PIM1-deficient ( Apoe -/- Lyz2 Cre/+ Pim1 fl/fl ) and their littermate control ( Apoe ⁻/⁻ Pim1 fl/fl ) mice a high-fat diet for 12 weeks. We then evaluated the plaque formation in their aortic sinuses and arches. Results: Deletion of Pim1 in Mφs reduced CD36 protein expression by up to 96.7% compared to WT controls. This led to a 49.6% decrease in foam cell formation and a 25.5% reduction in cellular cholesterol after oxLDL treatment. Pharmacological inhibition of PIM kinase activity in WT Mφs also impaired oxLDL handling, with a 64.5% reduction in binding and a 57.9% in uptake. Bulk RNA-seq revealed that Pim1 deficiency downregulated PPARγ signaling. Treatment with a PPARγ agonist restored CD36 levels in the PIM1 knockdown Mφs, suggesting that PIM1 regulates CD36 through PPARγ. Moreover, PIM1 Mφ-specific deficiency caused a 69.4% reduction in atherosclerotic plaque formation. Conclusion: PIM1 acts as a key upstream regulator of CD36 by enhancing PPARγ activity in Mφs. The PIM1-CD36 axis promotes oxLDL binding, uptake, and foam cell formation. Targeting the PIM1/PPARγ/CD36 pathway could offer new ways to modulate Mφ lipid metabolism and reduce atherosclerotic plaque progression. Non-standard Abbreviations and Acronyms: ELISA: enzyme-linked immunosorbent assay; HFD: high-fat diet; Mφs: macrophages; MCP-1: monocyte chemoattractant protein-1; ORO: oil red O; oxLDL: oxidized low-density lipoprotein; PBS: phosphate-buffered saline; PPARγ: peroxisome proliferator-activated receptor gamma; WT: wild type.
- Open Access
Na/K-ATPase Signaling in Adipocytes Promotes Atherosclerosis
BACKGROUND: Adipocyte dysfunction is closely associated with oxidative stress and chronic inflammation, which contribute to systemic metabolic disturbances and atherosclerosis. We previously identified Na/K-ATPase (NKA) α1 as a signal transducer that activates Src family kinases and promotes oxidative stress and inflammation in various cell types, including adipocytes and macrophages. NaKtide, a peptide inhibitor of NKA signaling, has been shown to reduce systemic oxidative stress and inflammation in vivo . Here, we investigated the role of adipocyte-specific NKA signaling in atherosclerosis. METHODS: Adipocyte-specific NaKtide (Adipo-NaKtide) was delivered to Apoe -/- mice using a lentiviral vector under the adiponectin promoter. The mice were then fed a Western Diet (WD) for 12 weeks to induce atherosclerosis and then assessed for atherosclerotic plaque burden the aortic arch and at the level of the aortic sinus. Inflammatory and oxidative stress markers were analyzed in adipose tissue and plasma. RESULTS: Adipo-NaKtide reduced atherosclerotic plaque area by 67% in the aortic arch and 47% in the aortic sinus. CD68 + macrophage and α-SMA + smooth muscle cell content in the aortic sinus were decreased by 45% and 53%, respectively. These vascular improvements were accompanied by dampened adipose tissue inflammation and oxidative stress, improved glucose tolerance, and lowered systemic inflammation. CONCLUSIONS: These findings highlight a critical contributing role for adipocyte NKA signaling in atherosclerosis, suggesting an important endocrine and/or paracrine influence of adipose tissue on large artery atherogenesis, and supporting the therapeutic potential of targeting NKA in cardiometabolic disease.
Open AccessNa/K-ATPase Signaling in Adipocytes Promotes Atherosclerosis
BACKGROUND: Adipocyte dysfunction is closely associated with oxidative stress and chronic inflammation, which contribute to systemic metabolic disturbances and atherosclerosis. We previously identified Na/K-ATPase (NKA) α1 as a signal transducer that activates Src family kinases and promotes oxidative stress and inflammation in various cell types, including adipocytes and macrophages. NaKtide, a peptide inhibitor of NKA signaling, has been shown to reduce systemic oxidative stress and inflammation in vivo . Here, we investigated the role of adipocyte-specific NKA signaling in atherosclerosis. METHODS: Adipocyte-specific NaKtide (Adipo-NaKtide) was delivered to Apoe -/- mice using a lentiviral vector under the adiponectin promoter. The mice were then fed a Western Diet (WD) for 12 weeks to induce atherosclerosis and then assessed for atherosclerotic plaque burden the aortic arch and at the level of the aortic sinus. Inflammatory and oxidative stress markers were analyzed in adipose tissue and plasma. RESULTS: Adipo-NaKtide reduced atherosclerotic plaque area by 67% in the aortic arch and 47% in the aortic sinus. CD68 + macrophage and α-SMA + smooth muscle cell content in the aortic sinus were decreased by 45% and 53%, respectively. These vascular improvements were accompanied by dampened adipose tissue inflammation and oxidative stress, improved glucose tolerance, and lowered systemic inflammation. CONCLUSIONS: These findings highlight a critical contributing role for adipocyte NKA signaling in atherosclerosis, suggesting an important endocrine and/or paracrine influence of adipose tissue on large artery atherogenesis, and supporting the therapeutic potential of targeting NKA in cardiometabolic disease.
- 1 July 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (7) , 1087-1089
Just Say NO to CD36 Expression: A Regulatory Pathway With Implications in Many Chronic Diseases
- 1 July 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (7) , 1087-1089
Just Say NO to CD36 Expression: A Regulatory Pathway With Implications in Many Chronic Diseases
- Open Access
- 3 June 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (16)
Chronic diseases alter the platelet rheostat to promote hyperreactivity and thrombosis
Platelet hyperreactivity, defined as enhanced sensitivity to activation in response to classical agonists, contributes to the increased risk of arterial thrombosis associated with chronic inflammatory diseases. In this issue of the JCI , Kong and colleagues used an unbiased proteomic approach to identify elevated SEC61B in platelets from patients with diabetes and from hyperglycemic mice. Typically, SEC61B participates in protein transport within the endoplasmic reticulum (ER), but it can also act as an ion channel that allows calcium to leak from ER to cytoplasm. The authors showed that elevated SEC61B expression caused increased calcium leak, elevated basal cytoplasmic calcium concentrations, and platelet hyperreactivity. In vitro and in vivo pharmacological interventions to alter calcium homeostasis through this pathway affected platelet reactivity. The results of this work are consistent with those of previous studies showing that platelets from patients with chronic diseases behaved differently than those from healthy participants. These findings identify potential disease-specific targets to prevent and treat arterial thrombosis.
- 3 June 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (16)
Open AccessChronic diseases alter the platelet rheostat to promote hyperreactivity and thrombosis
Platelet hyperreactivity, defined as enhanced sensitivity to activation in response to classical agonists, contributes to the increased risk of arterial thrombosis associated with chronic inflammatory diseases. In this issue of the JCI , Kong and colleagues used an unbiased proteomic approach to identify elevated SEC61B in platelets from patients with diabetes and from hyperglycemic mice. Typically, SEC61B participates in protein transport within the endoplasmic reticulum (ER), but it can also act as an ion channel that allows calcium to leak from ER to cytoplasm. The authors showed that elevated SEC61B expression caused increased calcium leak, elevated basal cytoplasmic calcium concentrations, and platelet hyperreactivity. In vitro and in vivo pharmacological interventions to alter calcium homeostasis through this pathway affected platelet reactivity. The results of this work are consistent with those of previous studies showing that platelets from patients with chronic diseases behaved differently than those from healthy participants. These findings identify potential disease-specific targets to prevent and treat arterial thrombosis.
- Open Access
- 9 January 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (1) , 83
Targeting Cysteine Oxidation in Thrombotic Disorders
Oxidative stress increases the risk for clinically significant thrombotic events, yet the mechanisms by which oxidants become prothrombotic are unclear. In this review, we provide an overview of cysteine reactivity and oxidation. We then highlight recent findings on cysteine oxidation events in oxidative stress-related thrombosis. Special emphasis is on the signaling pathway induced by a platelet membrane protein, CD36, in dyslipidemia, and by protein disulfide isomerase (PDI), a member of the thiol oxidoreductase family of proteins. Antioxidative and chemical biology approaches to target cysteine are discussed. Lastly, the knowledge gaps in the field are highlighted as they relate to understanding how oxidative cysteine modification might be targeted to limit thrombosis.
- 9 January 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (1) , 83
Open AccessTargeting Cysteine Oxidation in Thrombotic Disorders
Oxidative stress increases the risk for clinically significant thrombotic events, yet the mechanisms by which oxidants become prothrombotic are unclear. In this review, we provide an overview of cysteine reactivity and oxidation. We then highlight recent findings on cysteine oxidation events in oxidative stress-related thrombosis. Special emphasis is on the signaling pathway induced by a platelet membrane protein, CD36, in dyslipidemia, and by protein disulfide isomerase (PDI), a member of the thiol oxidoreductase family of proteins. Antioxidative and chemical biology approaches to target cysteine are discussed. Lastly, the knowledge gaps in the field are highlighted as they relate to understanding how oxidative cysteine modification might be targeted to limit thrombosis.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer
There is a strong correlation between myeloid-derived suppressor cells (MDSC) and resistance to immune checkpoint blockade (ICB), but the detailed mechanisms underlying this correlation are largely unknown. Using single-cell RNA sequencing analysis in a bilateral tumor model, we found that immunosuppressive myeloid cells with characteristics of fatty acid oxidative metabolism dominate the immune-cell landscape in ICB-resistant subjects. In addition, we uncovered a previously underappreciated role of a serine/threonine kinase, PIM1, in regulating lipid oxidative metabolism via PPARγ-mediated activities. Enforced PPARγ expression sufficiently rescued metabolic and functional defects of Pim1−/− MDSCs. Consistent with this, pharmacologic inhibition of PIM kinase by AZD1208 treatment significantly disrupted the myeloid cell–mediated immunosuppressive microenvironment and unleashed CD8+ T-cell–mediated antitumor immunity, which enhanced PD-L1 blockade in preclinical cancer models. PIM kinase inhibition also sensitized nonresponders to PD-L1 blockade by selectively targeting suppressive myeloid cells. Overall, we have identified PIM1 as a metabolic modulator in MDSCs that is associated with ICB resistance and can be therapeutically targeted to overcome ICB resistance.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer
There is a strong correlation between myeloid-derived suppressor cells (MDSC) and resistance to immune checkpoint blockade (ICB), but the detailed mechanisms underlying this correlation are largely unknown. Using single-cell RNA sequencing analysis in a bilateral tumor model, we found that immunosuppressive myeloid cells with characteristics of fatty acid oxidative metabolism dominate the immune-cell landscape in ICB-resistant subjects. In addition, we uncovered a previously underappreciated role of a serine/threonine kinase, PIM1, in regulating lipid oxidative metabolism via PPARγ-mediated activities. Enforced PPARγ expression sufficiently rescued metabolic and functional defects of Pim1−/− MDSCs. Consistent with this, pharmacologic inhibition of PIM kinase by AZD1208 treatment significantly disrupted the myeloid cell–mediated immunosuppressive microenvironment and unleashed CD8+ T-cell–mediated antitumor immunity, which enhanced PD-L1 blockade in preclinical cancer models. PIM kinase inhibition also sensitized nonresponders to PD-L1 blockade by selectively targeting suppressive myeloid cells. Overall, we have identified PIM1 as a metabolic modulator in MDSCs that is associated with ICB resistance and can be therapeutically targeted to overcome ICB resistance.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer
There is a strong correlation between myeloid-derived suppressor cells (MDSC) and resistance to immune checkpoint blockade (ICB), but the detailed mechanisms underlying this correlation are largely unknown. Using single-cell RNA sequencing analysis in a bilateral tumor model, we found that immunosuppressive myeloid cells with characteristics of fatty acid oxidative metabolism dominate the immune-cell landscape in ICB-resistant subjects. In addition, we uncovered a previously underappreciated role of a serine/threonine kinase, PIM1, in regulating lipid oxidative metabolism via PPARγ-mediated activities. Enforced PPARγ expression sufficiently rescued metabolic and functional defects of Pim1−/− MDSCs. Consistent with this, pharmacologic inhibition of PIM kinase by AZD1208 treatment significantly disrupted the myeloid cell–mediated immunosuppressive microenvironment and unleashed CD8+ T-cell–mediated antitumor immunity, which enhanced PD-L1 blockade in preclinical cancer models. PIM kinase inhibition also sensitized nonresponders to PD-L1 blockade by selectively targeting suppressive myeloid cells. Overall, we have identified PIM1 as a metabolic modulator in MDSCs that is associated with ICB resistance and can be therapeutically targeted to overcome ICB resistance.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer
There is a strong correlation between myeloid-derived suppressor cells (MDSC) and resistance to immune checkpoint blockade (ICB), but the detailed mechanisms underlying this correlation are largely unknown. Using single-cell RNA sequencing analysis in a bilateral tumor model, we found that immunosuppressive myeloid cells with characteristics of fatty acid oxidative metabolism dominate the immune-cell landscape in ICB-resistant subjects. In addition, we uncovered a previously underappreciated role of a serine/threonine kinase, PIM1, in regulating lipid oxidative metabolism via PPARγ-mediated activities. Enforced PPARγ expression sufficiently rescued metabolic and functional defects of Pim1−/− MDSCs. Consistent with this, pharmacologic inhibition of PIM kinase by AZD1208 treatment significantly disrupted the myeloid cell–mediated immunosuppressive microenvironment and unleashed CD8+ T-cell–mediated antitumor immunity, which enhanced PD-L1 blockade in preclinical cancer models. PIM kinase inhibition also sensitized nonresponders to PD-L1 blockade by selectively targeting suppressive myeloid cells. Overall, we have identified PIM1 as a metabolic modulator in MDSCs that is associated with ICB resistance and can be therapeutically targeted to overcome ICB resistance.
- 12 November 2022
- Published by Elsevier in Translational Research
- Vol. 254, 68-76
A CD36 transmembrane domain peptide interrupts CD36 interactions with membrane partners on macrophages and inhibits atherogenic functions
- 12 November 2022
- Published by Elsevier in Translational Research
- Vol. 254, 68-76
A CD36 transmembrane domain peptide interrupts CD36 interactions with membrane partners on macrophages and inhibits atherogenic functions